November 3-6, 2024 • San Antonio

Exhibitor Approval Policy and Form

Thank you for your interest in exhibiting at ObesityWeek® 2024!

Our exhibit review committee must approve all new exhibitors to the show or existing companies who wish to display a new product or service.

Vendors or products not consistent with the mission of ObesityWeek® or its member societies to safely treat or prevent obesity and weight-related bias may be refused space.

Companies wishing to join ObesityWeek's list of approved exhibitors, please complete this form and upload it where indicated on your Exhibit Contract, or email it to sgarcia@obesity.org.

Please upload a product brochure to expedite the turn-around time for approval.

This information will be sent to the review board for approval. You will be notified within two business days of your approval status.

Please note: Any company displaying products or services at ObesityWeek® 2024 that have not been previously approved by the review committee or found non-compliant with the general rules and regulations in place for the show may be dismissed from the exhibit area without refund or other appeal.

Company Name: _____

Company Contact Email: _____

Company Website: _____

Company description, products and services:

_____

_____

_____

_____

_____

FDA Status: ___ Exempt ___ Cleared (*Please note conditions on next page) ___ N/A

Note: Exhibitors selling products from their booth spaces must post their refund policy in the booth in a manner both legible and clear and must explain the refund process clearly before taking payment for product in the booth. Attendee complaints regarding pricing and refunds will result in exhibitor's immediate removal from the exhibit hall.

We understand that our company is subject to final approval upon show opening and may be evicted from its rented space and further participation at ObesityWeek® Annual Meetings for violating the above policy.

Date: _____

Authorized Signature: _____

Title: _____

FDA Market Clearance

No product, apparatus, instrument, device, or drug that is the subject of litigation pending before the US Food & Drug Administration (FDA) may be exhibited. All exhibitors for which FDA market clearance applies shall have documentation from the FDA on all products being displayed available at the booth. The documentation should state the model and regulatory class of those products that have been determined to be medical devices, as defined by the Federal Food, Drug, and Cosmetic Act, Section 201(h).

All devices that have not obtained FDA market clearance and are intended for use on humans or that are not commercially available in the US will be permitted for exhibit only when accompanied by the appropriate signs that indicate their status. The following are signs that should be displayed: (1) “This device is not for distribution in the United States”; (2) “Device is limited by federal law for investigational use”; (3) “Cleared for marketing when intended for only”; (4) “Pending FDA market clearance.” The signs must be easily visible and placed on or near the device itself and on any graphics depicting the device.

All products to be exhibited at ObesityWeek® conference must be identified on this form and must include FDA market clearance status, if applicable. This form will become part of the original application and contract.

NOTE: Prior to receiving the FDA market clearance of a 510(k) for a device, a manufacturer is limited in what promotional activities may be undertaken with regard to the device. Prior to the clearance of a 510(k), a manufacturer may advertise or display the device, but the device may not be sold, given away, held, or offered for sale, nor may orders be solicited, even upon the qualification that orders cannot be filled until the FDA acts on the 510(k), unless the device is limited to research or investigational use.

The failure to file a 510(k) is a misbranding violation [21 USC 352(o)]. Please contact the FDA Office of Compliance regarding your responsibilities under the Federal Food, Drug, and Cosmetic Act at 301/594-4692.